

## **Our Speakers and Panellists**



**Dr Dinesh Arora** *Principal Health Specialist, Asian Development Bank* 



Chris Humphrey
Executive Director,
EU-ASEAN Business Council



Dr Ryan MacFarlane
Director, Crowell & Moring International &
Asia-Pacific Economic Cooperation (APEC)
Vaccines Task Force representative



**Prof. George Gotsadze** *President, Curatio International Foundation* 



Ada Wong Head of Public Affairs, Vaccines, JPAC & Asia, Sanofi



Lois Privor-Dumm, Director, Adult Vaccines, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health











# Opening speech



**Dr Dinesh Arora** *Principal Health Specialist, Asian Development Bank* 





# Keynote speech



## **Dr Ryan MacFarlane**

Director, Crowell & Moring International & Asia-Pacific Economic Cooperation (APEC) Vaccines Task Force representative

## **About the APEC Vaccines Task Force (VTF)**

#### **About the APEC Vaccines Task Force:**

- Development and endorsement of the APEC Action Plan on Vaccination Across the Life-Course
- Organization of policy dialogues, webinars, and workshops to promote implementation of the Action Plan
- Development of a regional dashboard to measure regional progress towards the goals included within the Action Plan

APEC VTF engagements have drawn over 1000 participants from key stakeholders in all 21 APEC economies























## **APEC Action Plan on Vaccination Across the Life-Course**

#### **Core Recommendations of the Action Plan:**

Economies should take measures to:

- 1. Promote recognition of the value of vaccination and vaccine innovation
- Prioritize access to and uptake of vaccination across the lifecourse
- 3. Build whole-of-government capacity in health security and pandemic preparedness
- 4. Strengthen confidence in vaccination and build resilient immunization programs
- Enable investment and innovation in vaccine R&D, manufacturing, and delivery
- 6. Accelerate regulatory harmonization for vaccines across APEC economies
- 7. Establish prove and innovative mechanism for sustainable immunization financing

By 2030, all 21 APEC member economies will have implemented resilient and sustainable life-course immunization programs, with the objective of achieving widespread uptake of vaccination across the life-course and thereby protecting the health and wellbeing of all populations.



Learn more at https://www.apec.org/vaccinestaskforce/Action-Plan








## APEC Regional Dashboard on Vaccination Across the Life-Course

- The APEC Regional Dashboard on Vaccination Across the Life-Course ('Dashboard') is an initiative to provide a snapshot of the status of vaccination programs in APEC, using the goals, policy targets, and key indicators set forth in the Action Plan.
- The Dashboard is comprised of over 15 measures directly related to the pillars in the Action Plan, as well as best practices from economies.
- The results of the Dashboard demonstrate success in meeting several measures related to the Action Plan.







# APEC Regional Dashboard on Vaccination Across the Life-Course: Key Findings

Many economies do not include societal and economic benefits of vaccination in existing value assessment frameworks.

Consistent with global trends, immunization programs in APEC economies are strongest for pediatric populations, with all economies including recommendations for children in immunization schedules.

While many economies met >70% vaccination rates for DTP, MMR, and HPV vaccines between 2019-2021, additional efforts to strengthen vaccine access are needed to reach >90% coverage rates.

81% of APEC economies have either plans or legislation that supports financing of routine vaccines.

results of the Dashboard The demonstrate success in meeting several measures related Action Plan. To continue progress towards the 7 pillars, economies should leverage the Action Plan, which lays out specific actions support to immunization system strengthening, development sustainable of immunization policies, and cross-sector collaboration.













## Sustainable Financing for COVID-19 and Adult Vaccinations in 40 ADB's client countries

Presented by




**Prof. George Gotsadze** President, Curatio International Foundation



30 Years for Better Health Systems

The views expressed in this publication are those of the authors and do not necessarily reflect the views and policies of the Asian Development Bank (ADB), its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy of the data included in this publication and accepts no responsibility for any consequence of their use. Reference to specific companies or products does not imply any endorsement or recommendation from ADB in preference to others of a similar nature. By making any designation of or reference to a particular territory or geographic area, or by using the term "country" in this document, ADB does not intend to make any judgments as to its legal or other status.

## Study Objectives








# Study Coverage

- Countries: All 40 Developing Member Countries (DMCs) of the Asian Development Bank
- Vaccines: WHO recommended vaccines for >18 years and included or planned for introduction in DMCs' national immunization schedule
- Estimated costs included:
  - Vaccine requirements inclusive of wastage rates
  - Ancillary supply costs
  - Vaccine delivery i.e., health system costs
- **Temporal Coverage:** 5-year period (2023–2027)
- **Fiscal impact analysis** relative to:
  - General Government expenditure and
  - Government expenditure on health




Developing Member Countries Source: https://www.devex.com



## Adult Immunization Policies & National Targets


#### **Vaccines in National Policies**



- DMCs variably adopted WHO recommendations in terms of both the selection of vaccines and the population group targeted for vaccination
- Only Armenia had coverage target for Influenza for 2023 and beyond
- Countries variable selected target groups for adult immunization and
- Achieved variable performance, different from what has been reported internationally

## Total Cost of Delivering Adult Immunization


Average per Capita Cost for 2023–2027 (\$)



- There is a marked variation in the average cost per capita to deliver COVD-19 and adult immunization programs across developing member countries
- Three factors explain these differences: (i) the desired coverage targets; (ii) COVID-19 vaccine policies related to the target population and coverage targets for primary and booster doses; and (iii) high delivery costs in some DMCs, especially most of the Pacific small island developing states.


## Costs by Antigen

## Vaccination Program Costs by Antigen, 2023–2027




## Costs by Cost Categories

#### Vaccination Program Costs by Categories, 2023–2027



- Vaccines and ancillary supplies constitute the major costs for adult immunization programs.
- In most countries, products (vaccines, supplies) are responsible for over 50% of the immunization program costs
- COVID-19 vaccines cost more than all the other adult vaccines combined in most countries.

# Expected Fiscal Burden Arising from COVID-19 and Adult Vaccination Programs



- There is a considerable variation across countries in the fiscal burden resulting from COVID-19 and adult immunization programs. Obviously COVID-19 is a major cost driver.
- As a percentage of the GGHE, these programs would constitute a minimum of 0.01% of GGHE in Thailand to a maximum of 1.7% in Myanmar
- Uncertainty in delivery costs and the price of vaccines and consumables, means that there is considerable variability in the estimated fiscal impact.

## Recommendations

There is need for greater education and advocacy efforts to support adult vaccination uptake on a country and regional level

Advocacy and resource mobilization will benefit from cost-benefit studies similar to those carried for childhood immunization

Optimal selection of target vaccines and population groups and vaccine coverage targets could help balance financial needs with available funding

Vaccine price negotiation or arrangements for pooled procurement could help reduce vaccine prices and in that make programs more affordable

Multi-pronged strategies would be required to increase the affordability of adult vaccination programs and build adult vaccination capacity at scale, which would help ensure immediate health gains as well as better preparedness for future pandemics.

## **Thank You**

#### Forthcoming Publication and suggested citation

Gotsadze G, Chikovani I, Gzirishvili D, Zurabishvili N, Coghlan B, Dutta A, Yiengprugsawan VS, Osewe P, Goguadze K. 2023. Adult vaccination in Asia and the Pacific: Policies, Financial Needs, and Fiscal Impacts. Asian Development Bank.



# Life-Course Immunisation for Older Adults in Asia: A Health Economics Case





# Life-Course Immunisation: Preparing ASEAN for an Ageing Society



- Immune function goes into decline as individuals age
- Vaccination remains one of the most cost-effective interventions available to protect against infectious diseases













# Life-Course Immunisation: A Cost-Effective Public Health Intervention


Vaccination for elderly vaccines such as influenza and pneumococcal

Prevent mortality following hospitalisation by 47% in Malaysia

The COVID-19 pandemic shone a spotlight that preventive care, such as vaccination, not only saves lives, but also results in savings for the economy.




Prevents up to **77,000** mortality cases



and **5,300** excess deaths from influenza infections annually in the Philippines

# Life-Course Immunisation: Preparing ASEAN for an Ageing Society





By 2030, most member countries in the Association of Southeast Asian Nations (ASEAN), including Vietnam, Malaysia and Indonesia, will become ageing societies, while Singapore and Thailand will become aged ones.







# Life-Course Immunisation: Preparing ASEAN for an Ageing Society

#### **Thailand**

Free influenza vaccines, for 7 high-risk groups, including the elderly

## **Philippines**

Provide country's citizens with free vaccination against diseases (influenza virus, tetanus, shingles, measles)

## **Singapore**

Free Vaccination for elderly >65 years

Southeast Asia falls significantly short of the 75% immunisation target rate set by the World Health Organization

Elderly vaccine is not yet part of the national immunisation programme in Malaysia, Vietnam and Indonesia.





sanofi

# **Life-Course Immunisation: Sick Care to Preventive Care**



**Addressing this problem** 

Rapid state of ageing in ASEAN

Lack of proper implementation and widespread adoption of life-course immunisation in ASEAN



could bring about cost savings of up to USD 50,000 per qualityadjusted life year



Overarching barrier: Lack of policy framework and implementation

Delivery barriers: Lack of awareness and vaccine hesitancy

Financial barriers: Lack of financial support rendered to older people for vaccinations








# Life-Course Immunisation: A Health Economics Case



## Objectives:



Make the case for the **value of life-course immunisation** and its **increased investment** in
Southeast Asia among key decision makers, such as policymakers



Drive real-world health economics solution, by proposing innovative healthcare financing models that can be utilised to expand immunisation programmes to include the elderly population







## Who is eligible?

## Categories:

### **Rising Stars**

Aged between 18-31 years old, and currently enrolled in an educational institution or with five years or less of professional working experience in healthcare/public policy/health economics

## **Working Professionals**

Aged 32 years old and above or with at least eight years of professional working experience in healthcare/public policy/health economics

## Participating countries:



















## To learn more about the ideation initiative, visit:

https://healthyageingasean.org/life-courseimmunisation-for-older-adults-in-asia/

or scan the QR code below





# Panel discussion

sanofi

## A quick introduction of our Panellists

#### **Moderator**



Chris Humphrey
Executive Director,
EU-ASEAN Business Council

#### **Panellist**



Prof. George Gotsadze
President, Curatio
International Foundation

#### **Panellist**



Lois Privor-Dumm

Director, Adult Vaccines,
International Vaccine Access
Center, Johns Hopkins
Bloomberg School of Public
Health

#### **Panellist**



Dr Ryan MacFarlane
Director, Crowell & Moring
International & Asia-Pacific
Economic Cooperation
(APEC) Vaccines Task Force
representative



# Question & answers











# **Closing remarks**



Ada Wong Head of Public Affairs, Vaccines, JPAC & Asia, Sanofi

# For populations to age healthily tomorrow, we need to invest in vaccines today



**Ground-up advocacy** and **strong political will** are key to drive vaccine action



Concerted effort to drive recognition of the wider socioeconomic benefits of immunisation



**Tailored innovative financing models** are needed for countries with varying resources





Registration opens for submission

26 Sep 2023 - 17 Nov 2023



**Submission deadline** 17 Nov 2023



## **Closing webinar**

Announcement and presentation of best submission

05 Dec 2023 (Via Zoom)

## To learn more about the ideation initiative:



https://healthyageingasean.org/lifecourse-immunisation-for-olderadults-in-asia/







